Compare Amgen, Inc. (AMGN) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Otis Worldwide Corp — how do they compare? Amgen, Inc. trades at $417.52 (market cap $224.14B), while Otis Worldwide Corp trades at $73.55 (market cap $27.80B). The key difference: Amgen, Inc. is far larger — about 8.1× Otis Worldwide Corp's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | OTIS | |
|---|---|---|
Market Cap | $224.14B | $27.80B |
Sector | Health | Industrials |
52-Week High | $417.20 | $93.62 |
52-Week Low | $271.18 | $69.34 |
Enterprise Value | $267.45B | $35.84B |
Dividend Yield | 2.43% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Otis Worldwide (OTIS) trades at $72.87, down 1.51% over 24 hours, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings beat estimates but saw margin pressures and full-year guidance cuts. The company maintains strong service segment growth, with 9% organic sales increase, while facing headwinds in new equipment demand and labor costs. Valuation metrics show a P/E of 18.78 and P/S of 1.91, below historical averages after a 19% year-to-date decline.
Outlook is mixed: analyst consensus targets $92.50 with 47% buy ratings, but near-term risks include persistent margin compression and weak equipment sales. Long-term potential hinges on service margin expansion and modernization backlog execution, though investor sentiment remains cautious amid earnings misses and macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
